Targets › GABRB1
4 programs from 4 companies in 4 trials: 2 Phase 4, 1 Phase 2, 1 Phase 3; Other, Respiratory, Psychiatry; next expected readout Dec 2026.
Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain. GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain one or two GABA active binding sites located at the alpha and beta subunit interfaces, depending on subunit composition (By…. (UniProt, P18505)
Open in Phaseline: the race on GABRB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VA Office of Research and Development | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 4 | Sleep Disordered Breathing | Dec 2026 |
| University of Southern California | Zolpidem Tartrate GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 4 | Spine Fusion | Jan 2029 |
| Emory University | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 3 | Orthopedic Trauma | Jul 2027 |
| Stanford University | Zolpidem GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | GABRA1, GABRG2, GABRB1 | Phase 2 | Autism | Apr 2028 |
Sleep Disordered Breathing (1) Autism (1) Spine Fusion (1) Orthopedic Trauma (1)
small molecule (4)
VA Office of Research and Development (1) Stanford University (1) University of Southern California (1) Emory University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.